RETA stock forecast
Our latest prediction for Reata Pharmaceuticals, Inc.'s stock price was made on the June 22, 2017 when the stock price was at 29.26$.
In the short term (2weeks), RETA's stock price should outperform the market by 3.34%. During that period the price should oscillate between -7.67% and +9.87%.
In the medium term (3months), RETA's stock price should outperform the market by 0.51%. During that period the price should oscillate between -18.85% and +24.01%.Get email alerts
Create a solid portfolio with RETA
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
At the moment the company generates 15M USD in revenues.
On its last earning announcement, the company reported a loss of -10.93$ per share.
The book value per share is -5.66$
Three months stock forecastJune 22, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|